Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
|Videos|May 5, 2017
Eric Vachon on the Effect of Complexity on Adherence with Kinase Inhibitors
Author(s)Eric Vachon, BSN
Eric Vachon, BSN, PhD candidate, discusses the importance of taking all variables of complexity into account when considering adherence to kinase inhibitors.
Advertisement
Eric Vachon, BSN, PhD candidate, Michigan State University, discusses the many variables of complexity that can effect adherence to kinase inhibitors.
The regimen for kinase inhibitors is the most complex. Many current studies focus only on the issue of continuous versus cycling. However, there are other considerations that Vachon is studying in his own research.
Advertisement
Related to this article
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
2
Beyond the Treatment Center: Exploring Equine Assisted Wellness
3
Future Directions in Metastatic Triple-Negative Breast Cancer Care
4
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
5